{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:39:17Z","timestamp":1779323957937,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2016,6,10]],"date-time":"2016-06-10T00:00:00Z","timestamp":1465516800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s12325-016-0354-1","type":"journal-article","created":{"date-parts":[[2016,6,10]],"date-time":"2016-06-10T06:29:28Z","timestamp":1465540168000},"page":"1169-1179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir\/Asunaprevir"],"prefix":"10.1007","volume":"33","author":[{"given":"Dennis","family":"Hernandez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Kirov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saumya","family":"Pant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fiona","family":"McPhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,10]]},"reference":[{"issue":"1","key":"354_CR1","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep.27259","volume":"61","author":"JP Messina","year":"2015","unstructured":"Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61(1):77\u201387.","journal-title":"Hepatology"},{"issue":"10","key":"354_CR2","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1002\/jmv.23661","volume":"85","author":"MH Seong","year":"2013","unstructured":"Seong MH, Kil H, Kim YS, et al. Clinical and epidemiological features of hepatitis C virus infection in South Korea: a prospective, multicenter cohort study. J Med Virol. 2013;85(10):1724\u201333.","journal-title":"J Med Virol"},{"issue":"2","key":"354_CR3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3350\/cmh.2012.18.2.219","volume":"18","author":"EJ Cho","year":"2012","unstructured":"Cho EJ, Jeong SH, Han BH, Lee SU, Yun BC, Park ET. Hepatitis C virus (HCV) genotypes and the influence of HCV subtype 1b on the progression of chronic hepatitis C in Korea: a single center experience. Clin Mol Hepatol. 2012;18(2):219\u201324.","journal-title":"Clin Mol Hepatol."},{"issue":"9859","key":"354_CR4","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095\u2013128.","journal-title":"Lancet"},{"issue":"1 Suppl","key":"354_CR5","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","volume":"61","author":"E Gower","year":"2014","unstructured":"Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45\u201357.","journal-title":"J Hepatol"},{"issue":"7294","key":"354_CR6","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","volume":"465","author":"M Gao","year":"2010","unstructured":"Gao M, Nettles RE, Belema M, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465(7294):96\u2013100.","journal-title":"Nature"},{"issue":"10","key":"354_CR7","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1128\/AAC.01186-12","volume":"56","author":"F McPhee","year":"2012","unstructured":"McPhee F, Sheaffer AK, Friborg J, et al. preclinical profile and characterization of the hepatitis C virus NS3 protease inhibitor asunaprevir (BMS-650032). Antimicrob Agents Chemother. 2012;56(10):5387\u201396.","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"354_CR8","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jhep.2013.10.019","volume":"60","author":"AS Lok","year":"2014","unstructured":"Lok AS, Gardiner DF, H\u00e9zode C, et al. Randomized trial of daclatasvir and asunaprevir with or without PegIFN\/RBV for hepatitis C virus genotype 1 null responders. J Hepatol. 2014;60(3):490\u20139.","journal-title":"J Hepatol"},{"issue":"4","key":"354_CR9","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","volume":"58","author":"Y Suzuki","year":"2013","unstructured":"Suzuki Y, Ikeda K, Suzuki F, et al. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013;58(4):655\u201362.","journal-title":"J Hepatol"},{"issue":"6","key":"354_CR10","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59(6):2083\u201391.","journal-title":"Hepatology"},{"issue":"9954","key":"354_CR11","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S0140-6736(14)61059-X","volume":"384","author":"M Manns","year":"2014","unstructured":"Manns M, Pol S, Jacobson IM, et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384(9954):1597\u2013605.","journal-title":"Lancet"},{"issue":"1","key":"354_CR12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jgh.13073","volume":"31","author":"H Kumada","year":"2016","unstructured":"Kumada H, Suzuki F, Suzuki Y, et al. Randomized comparison of daclatasvir\u00a0+\u00a0asunaprevir versus telaprevir\u00a0+\u00a0peginterferon\/ribavirin in Japanese hepatitis C virus patients. J Gastroenterol Hepatol. 2016;31(1):14\u201322.","journal-title":"J Gastroenterol Hepatol"},{"key":"354_CR13","doi-asserted-by":"publisher","unstructured":"Wei L, Zhang M, Xu M, et al. A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin. J Gastroenterol Hepatol. 2016. doi: 10.1111\/jgh.13379 [Epub ahead of print].","DOI":"10.1111\/jgh.13379"},{"issue":"4","key":"354_CR14","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jhep.2012.11.012","volume":"58","author":"Y Karino","year":"2013","unstructured":"Karino Y, Toyota J, Ikeda K, et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013;58(4):646\u201354.","journal-title":"J Hepatol"},{"issue":"7","key":"354_CR15","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s12325-015-0221-5","volume":"32","author":"F McPhee","year":"2015","unstructured":"McPhee F, Suzuki Y, Toyota J, et al. High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5A polymorphisms. Adv Ther. 2015;32(7):637\u201349.","journal-title":"Adv Ther."},{"issue":"3","key":"354_CR16","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s00535-015-1106-8","volume":"51","author":"Y Uchida","year":"2016","unstructured":"Uchida Y, Kouyama J, Naiki K, et al. Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing. J Gastroenterol. 2016;51(3):260\u201370.","journal-title":"J Gastroenterol"},{"issue":"6","key":"354_CR17","doi-asserted-by":"crossref","first-page":"e0130022","DOI":"10.1371\/journal.pone.0130022","volume":"10","author":"S Yoshimi","year":"2015","unstructured":"Yoshimi S, Ochi H, Murakami E, et al. Rapid, sensitive, and accurate evaluation of drug resistant mutant (NS5A-Y93H) strain frequency in genotype 1b HCV by invader assay. PLoS One. 2015;10(6):e0130022.","journal-title":"PLoS One"},{"issue":"2","key":"354_CR18","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1128\/JVI.80.2.643-653.2006","volume":"80","author":"C Pallier","year":"2006","unstructured":"Pallier C, Cast\u00e9ra L, Soulier A, et al. Dynamics of hepatitis B virus resistance to lamivudine. J Virol. 2006;80(2):643\u201353.","journal-title":"J Virol"},{"issue":"1","key":"354_CR19","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1128\/JCM.43.1.406-413.2005","volume":"43","author":"S Palmer","year":"2005","unstructured":"Palmer S, Kearney M, Maldarelli F, et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005;43(1):406\u201313.","journal-title":"J Clin Microbiol"},{"issue":"3","key":"354_CR20","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12072-015-9624-2","volume":"9","author":"Y Hirotsu","year":"2015","unstructured":"Hirotsu Y, Kanda T, Matsumura H, et al. HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. Hepatol Int. 2015;9(3):424\u201330.","journal-title":"Hepatol Int."},{"issue":"21","key":"354_CR21","doi-asserted-by":"crossref","first-page":"7400","DOI":"10.1093\/nar\/gkq655","volume":"38","author":"O Zagordi","year":"2010","unstructured":"Zagordi O, Klein R, D\u00e4umer M, Beerenwinkel N. Error correction of next-generation sequencing data and reliable estimation of HIV quasispecies. Nucleic Acids Res. 2010;38(21):7400\u20139.","journal-title":"Nucleic Acids Res"},{"issue":"5","key":"354_CR22","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.coviro.2011.07.008","volume":"1","author":"N Beerenwinkel","year":"2011","unstructured":"Beerenwinkel N, Zagordi O. Ultra-deep sequencing for the analysis of viral populations. Curr Opin Virol. 2011;1(5):413\u20138.","journal-title":"Curr Opin Virol."},{"issue":"4","key":"354_CR23","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1128\/AAC.02068-13","volume":"58","author":"E Murakami","year":"2014","unstructured":"Murakami E, Imamura M, Hayes CN, et al. Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin. Antimicrob Agents Chemother. 2014;58(4):2105\u201312.","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"354_CR24","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","volume":"54","author":"RA Fridell","year":"2010","unstructured":"Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54(9):3641\u201350.","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"354_CR25","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jcv.2012.04.024","volume":"54","author":"F Suzuki","year":"2012","unstructured":"Suzuki F, Sezaki H, Akuta N, et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J Clin Virol. 2012;54(4):352\u20134.","journal-title":"J Clin Virol"},{"issue":"14","key":"354_CR26","doi-asserted-by":"crossref","first-page":"E360","DOI":"10.1111\/hepr.12316","volume":"44","author":"M Miura","year":"2014","unstructured":"Miura M, Maekawa S, Sato M, et al. Deep sequencing analysis of variants resistant to the non-structural 5A inhibitor daclatasvir in patients with genotype 1b hepatitis C virus infection. Hepatol Res. 2014;44(14):E360\u20137.","journal-title":"Hepatol Res."},{"issue":"2","key":"354_CR27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/jvh.12271","volume":"22","author":"K Kosaka","year":"2015","unstructured":"Kosaka K, Imamura M, Hayes CN, et al. Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1. J Viral Hepat. 2015;22(2):158\u201365.","journal-title":"J Viral Hepat."},{"issue":"1","key":"354_CR28","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3851\/IMP2976","volume":"21","author":"H Kinugasa","year":"2016","unstructured":"Kinugasa H, Ikeda F, Takaguchi K, et al. Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection. Antivir Ther. 2016;21(1):37\u201344.","journal-title":"Antivir Ther."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0354-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-016-0354-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-016-0354-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T12:05:50Z","timestamp":1498305950000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-016-0354-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,10]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["354"],"URL":"https:\/\/doi.org\/10.1007\/s12325-016-0354-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,10]]}}}